Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Virax Biolabs Group Limited Ordinary Shares (VRAX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: VRAX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $3
1 Year Target Price $3
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -8.89% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.39M USD | Price to earnings Ratio - | 1Y Target Price 3 |
Price to earnings Ratio - | 1Y Target Price 3 | ||
Volume (30-day avg) 1 | Beta 1.76 | 52 Weeks Range 0.74 - 7.63 | Updated Date 06/29/2025 |
52 Weeks Range 0.74 - 7.63 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.61 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -58112.48% |
Management Effectiveness
Return on Assets (TTM) -47.66% | Return on Equity (TTM) -90.64% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -3518792 | Price to Sales(TTM) 39.9 |
Enterprise Value -3518792 | Price to Sales(TTM) 39.9 | ||
Enterprise Value to Revenue 48.99 | Enterprise Value to EBITDA 0.42 | Shares Outstanding 4341960 | Shares Floating 3825915 |
Shares Outstanding 4341960 | Shares Floating 3825915 | ||
Percent Insiders 6.63 | Percent Institutions 6.71 |
Analyst Ratings
Rating 1 | Target Price 3 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Virax Biolabs Group Limited Ordinary Shares
Company Overview
History and Background
Virax Biolabs Group Limited is a biotechnology company focused on the prevention, detection, and diagnosis of viral diseases. Founded recently, it aims to address gaps in the diagnostics and prevention market through novel technologies and strategic partnerships.
Core Business Areas
- Viral Disease Diagnostics: Development and commercialization of diagnostic test kits for various viral diseases, including COVID-19 and other infectious diseases.
- Prevention Solutions: Focus on preventative measures against viral infections, potentially including vaccine research or therapeutic development.
- Distribution and Commercialization: Establishment of a global distribution network to market and sell Virax Biolabs products to healthcare providers, laboratories, and consumers.
Leadership and Structure
Information regarding specific leadership and organizational structure is difficult to find without access to the company's official website and/or financial reports. The structure is likely hierarchical with specialized departments.
Top Products and Market Share
Key Offerings
- COVID-19 Diagnostic Test Kits: Rapid antigen and PCR tests for detecting SARS-CoV-2. Market share is evolving, with strong competition from Abbott (ABT), Roche (RHHBY), and QuidelOrtho (QDEL). Data on precise market share and revenue contribution are difficult to acquire due to its relatively new market status.
- Viral Disease Detection Platforms: Development of broad-spectrum viral detection platforms applicable to various infectious diseases. Current market share data is not available due to the newness of these products. Competitors are BioMerieux (BIM.PA) and Danaher (DHR).
Market Dynamics
Industry Overview
The diagnostics market is experiencing growth due to rising awareness of infectious diseases, increasing demand for rapid testing, and advancements in diagnostic technologies. The market is competitive, with large players and niche companies.
Positioning
Virax Biolabs Group Limited positions itself as an innovative player focused on emerging and underserved segments of the viral disease diagnostics market. Competitive advantages may include novel technologies, speed of development, or strategic partnerships.
Total Addressable Market (TAM)
The global in-vitro diagnostics market size was estimated at USD 93.2 billion in 2022 and is expected to reach USD 133.7 billion by 2030. Virax Biolabs is positioned to capture a portion of this TAM by focusing on specific viral disease segments. Realizing the actual TAM penetration will depend on execution of business strategies and acceptance in the market.
Upturn SWOT Analysis
Strengths
- Focus on Viral Disease Diagnostics
- Potential for Innovative Technologies
- Global Distribution Network Development
Weaknesses
- Limited Operating History
- Small Size Compared to Major Competitors
- Dependence on Product Approval
- Potential Capital Needs for Growth
Opportunities
- Expanding Diagnostics Market
- Strategic Partnerships
- New Product Development
- Geographic Expansion
Threats
- Intense Competition
- Regulatory Changes
- Technological Advancements by Competitors
- Economic Downturn Impacting Healthcare Spending
Competitors and Market Share
Key Competitors
- Abbott Laboratories (ABT)
- Roche Holding AG (RHHBY)
- QuidelOrtho Corporation (QDEL)
Competitive Landscape
Virax Biolabs Group Limited faces strong competition from established players with greater resources, distribution networks, and regulatory expertise. Virax must innovate to compete effectively.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is not readily available due to limited operating history.
Future Projections: Future projections are based on analyst expectations, which is difficult to obtain. They depend on the company's ability to commercialize products, secure partnerships, and manage costs.
Recent Initiatives: Recent strategic initiatives likely involve product development, distribution expansion, and partnerships to expand market reach.
Summary
Virax Biolabs Group Limited is a relatively new company focused on the viral disease diagnostics market. While the company has opportunities for growth through innovative products and strategic partnerships, it faces significant competition from established players and has limited operating history. Success hinges on the company's ability to effectively commercialize products and navigate regulatory hurdles. With high risk and high potential reward, investors should be cautius.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Press Releases
- Industry Reports
- Financial News Sources
- Market Research Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Virax Biolabs Group Limited Ordinary Shares
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2022-07-21 | Chairman & CEO Mr. James Foster | ||
Sector Healthcare | Industry Biotechnology | Full time employees 17 | Website https://viraxbiolabs.com |
Full time employees 17 | Website https://viraxbiolabs.com | ||
Virax Biolabs Group Limited, a biotechnology company, distributes, markets, and sells diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name. It also develops T-Cell IVD test kit for COVID-19, which intend to adapt for immunological profiling against multiple viral threats under the ViraxImmune Brand, as well as a proprietary mobile application for ViraxImmune that presents an individual's immunological profiling data and provide advice on the users' immune system. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, pharmaceutical companies, research institutions, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was founded in 2013 and is headquartered in Lanarkshire, the United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.